Last reviewed · How we verify
BTA-C585 oral capsule
BTA-C585 is an oral antiviral agent that inhibits viral replication through targeting of viral proteases or polymerases.
BTA-C585 is an oral antiviral agent that inhibits viral replication through targeting of viral proteases or polymerases. Used for Viral infection (specific indication not publicly disclosed).
At a glance
| Generic name | BTA-C585 oral capsule |
|---|---|
| Also known as | BTA585 |
| Sponsor | Biota Pharma Europe Limited |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
BTA-C585 is a small-molecule antiviral compound in development by Biota Pharma Europe Limited. While specific molecular details are limited in public literature, the compound is designed to interfere with viral replication machinery. The drug is being evaluated in Phase 2 clinical trials for antiviral indications.
Approved indications
- Viral infection (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers (PHASE1)
- Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study (PHASE2)
- Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BTA-C585 oral capsule CI brief — competitive landscape report
- BTA-C585 oral capsule updates RSS · CI watch RSS
- Biota Pharma Europe Limited portfolio CI